Rio Tinto and AMG Metals & Materials to assess low-carbon aluminium project in India

LONDON, April 17, 2025 /PRNewswire/ -- Rio Tinto and AMG Metals & Materials (AMG M&M), an energy transition solutions provider, have signed a Memorandum of Understanding (MOU) to jointly assess the feasibility of developing an integrated low-carbon aluminium project powered by renewable energy in India. AMG M&M is promoted by the two founders of Greenko and AM Green.

Together, the parties will consider the potential development of up to a 1 million tonnes per annum (Mtpa) primary aluminium smelter and 2 Mtpa of alumina production, both powered by renewable wind and solar energy firmed by pumped hydro storage. The development will comprise a study to evaluate a potential first phase 500,000 tonnes per annum primary aluminium smelter in a favourable location in India.

Rio Tinto Aluminium Chief Executive Jérôme Pécresse said: "This study is an important step in our ambition to grow our global, low-carbon aluminium footprint while exploring new project delivery approaches and opportunities in emerging markets. Partnering with AMG Metals & Materials enables us to assess how we can develop low-cost responsible aluminium production powered by renewable energy. With its rapid economic growth and strategic position, India is a compelling location for this potential project and aligns with our long-term vision for a globally more diverse and resilient aluminium business."

As part of the study, AMG M&M will examine a firmed renewable energy solution with Greenko, while Rio Tinto will explore a commercial alumina solution. The study will also assess smelting technology options to determine the most cost-effective solution for the project.

Group President of AMG Metals & Materials and Greenko Mahesh Kolli said: "Over the last few years, we have been able to deliver a multitude of decarbonization solutions comprising electricity, molecules, chemicals and fuels. We are excited to expand that further to the materials space. This MOU could deliver much needed low-carbon metal at scale to propel decarbonization initiatives in global supply chains across auto, construction, consumer packaging and many more segments."

About AMG Metals & Materials

AMG Metals & Materials is incorporated by Anil Chalamalasetty and Mahesh Kolli, the founders of Greenko Group, one of India's leading energy transition solutions providers, and AM Green, a global decarbonization solution provider. Greenko has a near-term operational renewable energy capacity of 10 GW across solar, wind and hydro and is building 100 GWh of single cycle storage capacity across India. AM Green is developing low-carbon ammonia projects across multiple locations in India with a goal to reach 5 Mtpa of green ammonia capacity by 2030. Its first plant currently under construction in Kakinada with a projected capacity of 1 Mtpa of green ammonia will be one of the world's largest RFNBO compliant green ammonia facilities, supporting efforts to achieve net zero targets both in India and OECD markets. AM Green is also developing production capabilities for other net zero molecules and chemicals including green caustic soda, e-methanol, olefins & biofuels for decarbonization in hard to abate industries. Further information at www.amgreen.com

Contacts

AMG Metals & Materials

Suheil Imtiaz
Public Affairs & Strategic Communication
suheil.m@amgreen.com

Rio Tinto
media.enquiries@riotinto.com

Media Relations,

Media Relations,

Media Relations,

United Kingdom

Australia

Canada

Matthew Klar

Matt Chambers

Simon Letendre

M +44 7796 630 637

M +61 433 525 739

M +1 514 796 4973

David Outhwaite

Michelle Lee

Malika Cherry

M +44 7787 597 493

M +61 458 609 322

M +1 418 592 7293

Rachel Pupazzoni

Vanessa Damha

M +61 438 875 469

M +1 514 715 2152

Media Relations,

US

Jesse Riseborough

M +1 202 394 9480

Investor Relations,

Investor Relations,

United Kingdom

Australia

Rachel Arellano

Tom Gallop

M: +44 7584 609 644

M +61 439 353 948

David Ovington

Amar Jambaa

M +44 7920 010 978

M +61 472 865 948

Laura Brooks

M +44 7826 942 797

Weiwei Hu

M +44 7825 907 230

Rio Tinto plc

Rio Tinto Limited

6 St James's Square

Level 43, 120 Collins Street

London SW1Y 4AD

Melbourne 3000

United Kingdom

Australia

T +44 20 7781 2000

T +61 3 9283 3333

Registered in England

Registered in Australia

No. 719885

ABN 96 004 458 404

riotinto.com
Category: General

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Rio Tinto and AMG Metals & Materials to assess low-carbon aluminium project in India

AUCKLAND, New Zealand, May 2, 2025 /PRNewswire/ -- Soft tissue regeneration company, Aroa Biosurgery, is pleased to announce a milestone in clinical evidence.

There are now over 100 peer-reviewed studies describing the efficacy of the company's proprietary AROA ECM technology.

AROA's most recent publication was a large retrospective analysis of real-world evidence (RWE) from wound care centers in the US, assessing the efficacy of the company's Endoform Natural^TM product in treating venous leg ulcers (VLUs), in comparison to a leading reconstituted collagen dressing.

VLU's are open sores that are hard-to-heal because of impaired blood flow and can be very debilitating and painful.  These types of wounds are difficult for clinicians to treat successfully. For example, only ~40% of VLUs can be healed after 3 months of treatment and there is a relatively high chance that these wounds will recur^[1].

The peer-reviewed study, entitled "Clinical Efficacy of Ovine Forestomach Matrix and Collagen/Oxidized Regenerated Cellulose for the Treatment of Venous Leg Ulcers: A Retrospective Comparative Real-World Evidence Study" was published in the open access journal 'International Wound Journal in April 2025.

The study compared 470 VLU's that had been treated with Endoform Natural to 360 VLU's that had been treated with a reconstituted collagen product. The study used existing data from 223 wound care centers with minimal inclusion or exclusion criteria so that 'real-world' use of both products could be compared.

"There is a growing awareness of RWE studies to validate clinical performance" says Chief Scientific Officer, Dr. Barnaby May. "These types of studies enable much larger patient numbers to be compared versus traditional randomized controlled trials. Given that RWE studies use data from 'real-world' use of a treatment, the results can be more meaningful, especially in wound care where there is a high degree of variability in how wounds are cared for and patient factors."

The study found that VLUs treated with Endoform Natural healed up to ~ 8 weeks faster versus the comparator group, and the chances of the wound healing were significantly improved when Endoform Natural was used as part of treatment.

The striking difference in the healing outcomes demonstrate the potential for considerable cost reductions and improvements in patient quality of life, due to the significant improvements seen when VLUs were treated using Endoform Natural.

Dr. Gregory Bohn MD was part of the research team. "I was first introduced to Endoform in 2012 and started using the product to treat my own patients with VLUs. This new data validates what I have seen in my own practice managing VLUs with Endoform."

This is the second large retrospective RWE comparing Endoform Natural to a leading reconstituted collagen dressing. A previous study included the analysis of over 2,200 diabetic foot ulcers (DFUs) and also demonstrated significantly faster healing of DFUs using Endoform Natural^[2].

The study is available online here.

[1] Kolluri R, Lugli M, Villalba L, Varcoe R, Maleti O, Gallardo F, et al. An estimate of the economic burden of venous leg ulcers associated with deep venous disease. Vasc Med. 2022;27(1):63-72.

[2] Bosque BA, Frampton C, Chaffin AE, Bohn GA, Woo K, DeLeonardis C, Lepow BD, Melin MM, Madu T, Dowling SG, May BCH. Retrospective real-world comparative effectiveness of ovine forestomach matrix and collagen/ORC in the treatment of diabetic foot ulcers. Int Wound J. 2022 May;19(4):741-753.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

AROA hits evidence milestone with real-world study validating the efficacy of Endoform in treating challenging venous leg ulcers.